New drug combo offers hope for older hodgkin lymphoma patients who Can't tolerate chemo
NCT ID NCT02758717
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two drugs—nivolumab and brentuximab vedotin—in 46 older adults (60+) or those unable to receive standard chemotherapy for untreated Hodgkin lymphoma. The goal is to see if this immunotherapy-based approach can shrink or eliminate tumors without the harsh side effects of traditional chemo. Participants receive the drugs intravenously over several cycles, and response is measured by PET scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and brentuximab vedotin
- What this could lead to
- If successful, this could offer a less toxic treatment option for older or frail patients with Hodgkin lymphoma, potentially controlling the disease without standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial (46 participants) with no control group, so results may not confirm effectiveness. Side effects from immunotherapy and the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE IB HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune booster before chemo may shrink hodgkin tumors with fewer drugs
- Immune booster may strengthen stem cell transplant against hodgkin lymphoma
- Two-Drug combo aims to outsmart resistant hodgkin lymphoma
- Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
- Can an old drug make immunotherapy work again for hodgkin lymphoma?
- New immunotherapy combo aims to boost hodgkin lymphoma remission